Trial of Lixisenatide in Early Parkinson’s Disease

G. Meissner, Wassilios; Rémy, Philippe; Giordana, Caroline; Maltête, David; Derkinderen, Pascal; Houéto, Jean‐Luc; Anheim, Mathieu; Bénatru, Isabelle; Boraud, Thomas; Brefel‐Courbon, Christine; Carrière, Nicolas; Catalá, Hélène; Charif, Mahmoud; Colin, Olivier; Corvol, Jean‐Christophe; Damier, Philippe; Dellapina, Estelle; Devos, David; Drapier, Sophie; Fabbri, Margherita; Ferrier, Vanessa; Foubert‐Samier, Alexandra; Frismand-Kryloff, Solène; Geny, Christian; Georget, Aurore; Germain, Christine; Grimaldi, Stéphan; Hardy, Clémence; Hopes, Lucie; Krystkowiak, Pierre; Laurens, Brice; Lefaucheur, Romain; Mariani, Louise‐Laure; Marquès, Ana; Marsé, Claire; Ory‐Magne, Fabienne; Rigalleau, Vincent; Salhi, Hayet; Saubion, Amandine; Stott, Simon; Thalamas, Claire; Thiriez, Claire; Tir, Mélissa; Wyse, Richard; Bénard, Antoine; Rascol, Olivier

doi:10.1056/nejmoa2312323

Public

Trial of Lixisenatide in Early Parkinson’s Disease

Published in New England Journal of Medicine • Apr 3, 2024

Authors:

Wassilios G. Meissner

Philippe Rémy

Caroline Giordana

Abstract

BACKGROUND: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease. METHODS: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide ...

Subject

Lixisenatide

Medicine

Parkinson's disease

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!